ArticleInternational journal of urology : official journal of the Japanese Urological Association2024

Editorial Comment from Dr Miyake to Real-world outcomes of avelumab plus axitinib as first-line therapy in patients with advanced renal cell carcinoma in Japan: A multicenter, retrospective, observational study (J-DART).

No numbers read from the abstract.

Not cited yet